Q32 Bio
QTTB
72 hedge funds and large institutions have $283M invested in Q32 Bio in 2026 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 8 closing their positions.
366% more capital invested
Capital invested by funds: $60.6M → $283M (+$222M)
238% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 8
66.35% more ownership
Funds ownership: 64.46% → 130.8% (+66%)
33% more funds holding
Funds holding: 54 → 72 (+18)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $3.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
+$26.3M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$19.6M |
| 3 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.5M |
| 4 |
O
OrbiMed
New York
|
+$15.7M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CG
Carlyle Group
Washington,
District of Columbia
|
-$8.71M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.72M |
| 3 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$2.06M |
| 4 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$1.58M |
| 5 |
ACA
Acorn Capital Advisors
New York
|
-$826K |
QTTB Hedge Fund Activity: Q2 2026 in Review
72 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Q32 Bio (QTTB) for Q2 2026, worth a combined $283M — up 366% from $60.6M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new QTTB positions and 8 closed out — a net gain of 19 holders — while 17 added to existing stakes and 14 trimmed.
The largest buyer was Boxer Capital Management, opening a new position worth an estimated $26.3M. The largest seller was Carlyle Group, cutting an estimated $8.71M.
- 72 institutional investors held Q32 Bio (QTTB) as of Q2 2026, up from 54 in Q1 2026.
- Funds reported $283M of Q32 Bio stock for Q2 2026, up 366% quarter-over-quarter.
- 27 funds opened new Q32 Bio positions in Q2 2026 and 8 closed out, a net change of +19 holders.
- The largest Q32 Bio buyer in Q2 2026 was Boxer Capital Management, an estimated $26.3M added.
- The largest Q32 Bio seller in Q2 2026 was Carlyle Group, an estimated $8.71M sold.
Based on aggregated 13F filings for Q2 2026.